Factors including age; sex; tumor size; PTV; biologically effective dose; presence or absence of chronic hepatitis; and baseline counts of RBCs, WBCs, PLTs, tumor necrosis factor-α (TNF-α) level, alpha-fetoprotein (AFP) level; and both baseline and post-treatment TPLC and CLP values at 10 days after SBRT were assessed in univariate analyses. This evidence concerns the gene AFP and chronic hepatitis.